|1.||de Sauvage, Frederic J: 6 articles (01/2011 - 06/2009)|
|2.||Yauch, Robert L: 5 articles (12/2012 - 09/2009)|
|3.||Rudin, Charles M: 4 articles (04/2011 - 09/2009)|
|4.||Hann, Christine L: 4 articles (04/2011 - 09/2009)|
|5.||Low, Jennifer A: 4 articles (04/2011 - 09/2009)|
|6.||Reddy, Josina C: 3 articles (12/2012 - 09/2009)|
|7.||LoRusso, Patricia M: 3 articles (04/2011 - 09/2009)|
|8.||Von Hoff, Daniel D: 3 articles (04/2011 - 09/2009)|
|9.||Tibes, Raoul: 3 articles (04/2011 - 09/2009)|
|10.||Gould, Stephen E: 3 articles (01/2011 - 09/2009)|
12/01/2011 - "The pivotal phase II trials have been completed on the Smoothened inhibitor known as GDC-0449; five other agents (BMS-833923, LDE225, LEQ506, IPI926, and TAK-441) have also shown promise in animal studies and early clinical trials and have shown some efficacy in a variety of cancers that are affected by the Hedgehog signaling pathway."
04/15/2011 - "This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed. "
03/01/2010 - "Long-term efficacy and safety studies of GDC-0449 in these conditions and other solid cancers are now underway. "
03/01/2010 - "The objective of this evaluation is to review the initial clinical studies of the hedgehog inhibitor, GDC-0449, in subjects with cancer. "
10/23/2009 - "GDC-0449, a drug that inhibits Hh signaling by targeting the serpentine receptor Smoothened (SMO), has produced promising anti-tumor responses in early clinical studies of cancers driven by mutations in this pathway. "
|2.||Basal Cell Carcinoma (Rodent Ulcer)
12/01/2010 - "Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma."
12/01/2010 - "To demonstrate the efficacy of the hedgehog pathway inhibitor GDC-0449 in the treatment of advanced basal cell carcinoma. "
01/01/2014 - "MEDLINE and PubMed were searched using the terms vismodegib, GDC-0449, RG3616, and basal cell carcinoma for relevant clinical trials through September 2013. "
08/01/2014 - "Vismodegib (GDC-0449, Genentech, USA), a small molecule inhibitor of the Hedgehog signalling pathway, has potent anti-tumour activity in advanced basal cell carcinoma (BCC). "
12/01/2010 - "GDC-0449 showed significant inhibitory activity in the treatment of advanced basal cell carcinoma."
01/01/2014 - "The present study sought to determine whether the Hedgehog (Hh) pathway is active and regulates the cell growth of cultured malignant pleural mesothelioma (MPM) cells and to evaluate the efficacy of pathway blockade using smoothened (SMO) antagonists (SMO inhibitor GDC-0449 or the antifungal drug itraconazole [ITRA]) or Gli inhibitors (GANT61 or the antileukemia drug arsenic trioxide [ATO]) in suppressing MPM viability. "
|4.||Lung Neoplasms (Lung Cancer)
03/01/2012 - "We demonstrate for the first time that GDC-0449 effectively reduces cell growth in lung cancer cell lines. "
03/01/2012 - "Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations."
03/01/2012 - "The Hh inhibitor GDC-0449 has been proven to be effective in some cancers but not yet in lung cancer. "
01/01/2012 - "GDC-0449 alters intracellular Ca(2+) homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells."
01/01/2012 - "The hedgehog pathway inhibitor GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells."
12/01/2014 - "Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma."
03/01/2012 - "We aimed at investigating whether GDC-0449 is effective in the lung cancer cell lines HCC (adenocarcinoma) and H1339 (small-cell-lung carcinoma), whether in these cell lines stem cell-like side populations (SPs) can be identified, and whether possible effects of GDC-0449 are mediated via SPs. "
|3.||arsenic trioxide (Trisenox)
|8.||Messenger RNA (mRNA)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Homologous Transplantation (Allograft)
|3.||Drug Therapy (Chemotherapy)